Abstract
Patients having cancer, infectious and other diseases suffer from drug resistance and systemic side effects owing to the conventional chemotherapeutics’ insolubility, toxicity, non-specificity, low therapeutic indices, and several limitations against biological barriers. To overcome these obstacles, nanotechnology-based metallic platinum nanoparticles (PtNPs) have attracted attention for targeted drug delivery and sustained release against the diseases for the cellular killing as antimicrobial and anticancer agents. PtNPs-based therapeutic systems have been utilized to avail their higher therapeutic efficacies with low concentrations against various diseases due to their suitable physico-chemical features such as shape, size, high surface to volume ratio, favorable bio-stability, easy membrane penetration, and easy surface functionalizations with cargos, ligands, peptides, antibodies and polymers for the targeted and controlled therapy against diseases. PtNPs may also be conjugated with other metals with drugs as suitable carriers for their chemo, photothermal / photoacoustic / magnetic therapies against tumors. This review demonstrates mainly the synthesis, functionalization, mechanism of action, biomedical application and toxicity of PtNPs as suitable nanomedicinal delivery system against diseases.
Keywords: Diseases; Platinum nanoparticles; Delivery system; Therapeutic efficacies
Publisher
Society of Pharmaceutical Tecnocrats
Reference188 articles.
1. 1. Mandal AK. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int J Polym Mater Polym Biomater. 2021; 70(4):287-97. https://doi.org/10.1080/00914037.2020.1713780
2. 2. National Institutes of Health (US). Biological sciences curriculum study NIH curriculum supplement series. In understanding emerging and re-emerging infectious diseases: National Institutes of Health (US). 2007; Bethesda, MD. https://www.ncbi.nhm.nih.gov/books/NBK 20370/ (accessed on 20 April 2017).
3. 3. Waarts MR, Stonestrom AJ, Park YC, Levine RL. Targeting mutations in cancer. J Clin Invest. 2022; 132(8):e154943. https://doi.org/10.1172/JCI154943 PMid:35426374 PMCid:PMC9012285
4. 4. Jin J, Wu X, Yin J, Li M, Shen J, Li J, et al. Identification of genetic mutations in cancer: Challenge and opportunity min the new era of targeted therapy. Front Oncol. 2019; 9:263. https://doi.org/10.3389/fonc.2019.00263 PMid:31058077 PMCid:PMC6477148
5. 5. Rivas-Dominguez A, Pastor N, Martinez-Lopez L, Colon-Perez J, Bermudez B, Orta ML. The role of DNA damage response in dysbiosis-induced colorectal cancer. Cells. 2021; 10(8):1934. https://doi.org/10.3390/cells10081934 PMid:34440703 PMCid:PMC8391204